It’s been a difficult week for atai Life Sciences, with the company’s stock price tacking a tumble as pre-IPO shares became eligible for trading. Despite efforts by insiders, including voluntary extended lock-ups announced by the company on Wednesday itself, ATAI was down nearly 40% on the lock-up expiry day. COMPASS Pathways looks set to enter a spot of bother, too. VICE’s Shayla Love broke the…


Previous articleMYND Life Sciences Acquires Rights for the Use of Psychedelics to Treat Alzheimer’s Disease and other Dementias
Next articleHAVN Life Enters into Definitive Agreement to Acquire Spore Life Sciences Inc.